Advancing clinical-grade tumor-infiltrating lymphocyte therapy manufacturing

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Advancing clinical-grade tumor-infiltrating lymphocyte therapy manufacturing

The field of adoptive cell therapy for solid malignancies have made groundbreaking strides using tumor-infiltrating lymphocytes (TILs). Despite the progress, there are still hurdles to overcome in TIL manufacturing. The journey to success lies in refining manufacturing protocols for a brighter clinical outlook.

Join this webinar and discover innovative cell manufacturing solutions. Learn how to generate tumor-reactive T cells (TRTs) for TIL therapy, all within a standardized and seamlessly automated framework.

Attend this webinar to learn about:

How to master closed system automation for the efficient production of TIL cell products
Solutions tailored to your clinical-scale TIL manufacturing needs
GMP-compliant cell sorting for specific tumor-reactive T cell subsets in a closed system

Arina Riabinska

R&D Team Coordinator, Personalized Immunotherapy at Miltenyi Biotec

Arina’s journey began with a master's in medical neurosciences, at the Charité, Berlin. A PhD in genetics followed at the University of Cologne, alongside two years as a postdoctoral researcher, where she explored T cell based immune surveillance. In her current role as an R&D team coordinator at Miltenyi Biotec she works on process development of personalized immunotherapies focusing on tumor-infiltrating lymphocytes (TILs) and tumor-reactive T cells (TRTs).